Professor Patrick Chinnery, an expert in diseases that affect mitochondria – the ‘batteries’ that power our cells – has been appointed as Professor of Neurology and Head of the Department of Clinical Neurosciences at the University of Cambridge. He will take up his appointment on 1 October.
Sugar sweetened drinks may give rise to nearly two million diabetes cases over ten years in the US and 80,000 in the UK, estimates a study published in the BMJ.
A ‘pill on a string’ developed by researchers at the University of Cambridge could help doctors detect oesophageal cancer – cancer of the gullet – at an early stage, helping them overcome the problem of wide variation between biopsies, suggests research published today in the journal Nature Genetics.
An experimental cystic fibrosis drug has been shown to prevent the disease’s damage to the liver, thanks to a world-first where scientists grew mini bile ducts in the lab.
Cambridge has been part of a successful £16 million bid to work with the MRC, GSK and four other UK universities in a unique open innovation research initiative aiming to improve scientists’ understanding of inflammatory diseases that present a serious burden to patients.
New research has identified an increased risk of brain haemorrhage from the combined use of antidepressant medicines and medicines such as ibuprofen. Should we be worried? Dr Rupert Payne from the Cambridge Centre for Health Services Research looks at the evidence.
Researchers at the University of Cambridge, in collaboration with the University of Edinburgh, have shown how a radioactive agent developed in the 1960s to detect bone cancer can be re-purposed to highlight the build-up of unstable calcium deposits in arteries, a process that can cause heart attack and stroke.
Life expectancy for people with a history of both cardiovascular disease and diabetes is substantially lower than for people with just one condition or no disease, a new study harnessing the power of ‘big data’ has concluded.
The hormones testosterone and cortisol may destabilise financial markets by making traders take more risks, according to a study published today in Scientific Reports.
AstraZeneca and the University of Cambridge today announced three new joint schemes to support more than 80 PhD scholarships and eight clinical lectureships over the next five years spanning translational science, basic and clinical research. Two of the schemes are co-funded by the NIHR Cambridge Biomedical Research Centre, a partnership between Cambridge University Hospitals and University of Cambridge.